Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism

Definitions

• the present invention relates to a method for the treatment of Gaucher ' s disease and other glycolipid storage diseases.
• Gaucher * s disease is a glycolytic storage disease caused by a genetic deficiency in activity of the catabolic enzyme beta- glucocerebrosidase. Beutler, Proc. Natl. Acad. Sci. USA 90, 5384-5390 (1993) . Manifestations of this disease are impaired hematopoiesis, bone fractures, a thinning of the bone cortex and massive enlargement of the spleen and liver.
• CEREDASE glucocerebrosidase
• CEREZYME recombinant human glucocerebrosidase
• Conjugates of the glucocerebrosidase enzyme with polyethylene glycol (PEG) have also been advanced by Enzon Inc. for treatment of Gaucher ' s disease. See, for example, U.S. Patent Nos. 5,705,153 and 5,620,884.
• Still another approach for treatment of the disease is gene therapy, which involves an ex vivo gene transfer protocol.
• N-butyldeoxynojirimycin and related N-alkyl derivatives of DNJ are known inhibitors of the N-linked oligo- saccharide processing enzymes, ⁇ -glucosidase I and II. Saunier et al . , J. Biol. Chem. 257. 14155-14161 (1982); Elbein , Ann. Rev. Biochem. 56. 497-534 (1987) . As glucose analogs, they also have potential to inhibit glycosyltransferases. Newbrun et al . , Arch. Oral Biol. 28. 516-536 (1983); Wang et al . , Tetrahedron Lett. 34.
• Patent 4,849,430 as an inhibitor of hepatitis B virus (HBV) as described by Block et al . , Proc. Natl. Acad. Sci. USA 91, 2235-2239 (1994), PCT Int'l. Appln. WO 95/19172.
• HBV hepatitis B virus
• a novel method for the treatment of a patient affected with Gaucher ' s disease or other such glycolipid storage diseases.
• the method comprises administering to said patient a therapeutically effective amount of a long-chain N-alkyl derivative of 1,5- dideoxy-1, 5-imino-D-glucitol having from nine to about 20 carbon atoms in the alkyl chain.
• the N-alkyl ⁇ ub ⁇ tituent thus can be, e.g, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, cis- 11-hexadecenyl, octadecyl, cis-13-octadecenyl, and eicosyl.
• a therapeutically effective amount is meant an amount effective in alleviating or inhibiting Gaucher' s disease or other such glycolipid storage diseases in said patient.
• the alkyl group in these long-chain N-alkyl-DNJ compounds preferably contains nine to ten carbon atoms (i.e., nonyl and decyl).
• a most preferred compound is N-nonyl-1, 5-dideoxy-l,5- imino-D-glucitol, also known as the N-nonyl derivative of deoxynojirimycin (DNJ) , which also is abbreviated herein as N- nonyl-DNJ.
• the long-chain alkyl groups are known to provide more hydrophobic properties to compounds than are the short-chain alkyl groups. That is, solubility with water decreases with increase in chain length and decrease in temperature. For example, at 46°C, caproic acid (short-chain hexyl group) dissolves 10% by weight of water, whereas ⁇ tearic acid (long-chain octadecyl group) dissolves only 0.92% even at the higher temperature of 69°C. Bailey's Industrial Oil and Fat Products, ed. Daniel Swern, 3d ed. 1964, p. 126.
• the long-chain N-alkyl derivatives of DNJ are known amino- ⁇ ugar compounds. They were originally described as members of a group of short-chain and long-chain N-alkyl derivatives of DNJ having both glucosidase I inhibitory activity and antiviral activity, although no data on the long-chain N-alkyl derivatives was disclosed. See, e.g., DE 3,737,523, EP 315,017 and U.S. Patent Nos. 4,260,622; 4,639,436; and 5,051,407.
• the activity of any specific analog cannot be predicted in advance.
• HIV human immunodeficiency virus
• slight changes in the structure of the N-substituent were shown to have pronounced effects upon the antiviral profile as reported by Fleet et al . , FEBS Lett. 237. 128-132 (1988).
• the N-butyl derivative of DNJ was unexpectedly found to be more than two log orders more effective as an inhibitor of HIV than the N-methyl analog and three log orders more effective than the N-ethyl analog.
• N-alkyl derivatives of DNJ for activity against glycolipid biosynthesis, the N-hexyl derivative of DNJ required a dose of 0.2 mg/ml, whereas the corresponding N-butyl analog required a dose of only 0.01-0.1.
• the N-methyl analog was inactive.
• effective carbon chain length of the N-alkyl group for thi ⁇ activity ranged from 2 to 8 according to U.S. Patent No. 5,472,969. No disclosure was made therein concerning the N-nonyl or other long-chain N-alkyl derivatives of DNJ.
• N-nonyl-DNJ has been reported to be effective as an inhibitor of the Hepatitis B virus (HBV) ba ⁇ ed on inhibition of alpha-glucosidases in the cellular endopla ⁇ mic reticulum (ER) according to Block et al . , Nature Medicine 4(5) 610-614 (1998).
• the effectiveness of the long-chain N-alkyl derivatives of DNJ in the method of the invention for treatment of Gaucher 's disease and other such glycolipid storage di ⁇ ea ⁇ es is illustratively demonstrated herein by inhibitory activity of N- nonyl and N-decyl DNJs against glycolipid bio ⁇ ynthe ⁇ is in Chinese hamster ovary (CHO) cells and human yeloid (HL-60) cells.
• CHO cells are known glycoprotein- ⁇ ecreting mammalian cells.
• a typical CHO cell line is CHO-Kl which i ⁇ available to the public from the American Type Culture Collection, Bethe ⁇ da, MD, under accession number ATCC CCL 61.
• HL-60 cells are human promyelocytic cells described by Collins et al . , Nature 270. 347-349 (1977). They are also readily available from the American Type Culture Collection under accession number ATCC CCL 240. Effective activity of N-nonyl-DNJ also is further illustratively demonstrated herein in conventional bovine kidney cells (e.g., MDBK, ATCC CCL 22) and hepato a cells (e.g., HepG2 , ATCC HB 8065) .
• conventional bovine kidney cells e.g., MDBK, ATCC CCL 22
• hepato a cells e.g., HepG2 , ATCC HB 8065
• the unpredictability of the N-nonyl-DNJ against glycolipid biosynthesis is demonstrated herein by its inhibitory activity in the foregoing two cell lines.
• the N-nonyl-DNJ was unexpectedly found to be from about ten- to about twenty-fold better in the CHO cells and about four hundred ti e ⁇ better in the HL-60 cell ⁇ than N-butyl-DNJ at equivalent concentrations.
• the N-decyl-DNJ was demonstrated to be an effective inhibitor in HL-60 cells at 50 times lower concentrations than N-butyl-DNJ.
• the N-nonyl-DNJ also exhibits a more dramatic difference than N-butyl-DNJ in uptake which permits its use at a ⁇ ub ⁇ tantially lower level.
• the N-nonyl-DNJ wa ⁇ taken up five times better into the brain than N-butyl-DNJ.
• the N-nonyl-DNJ is believed to be a substantially better compound than N-butyl-DNJ for treating glycolipid storage disorders which involve the non-sy ⁇ temic side.
• N-nonyl-DNJ and N-decyl-DNJ can be conveniently prepared by the N-nonylation or N-decylation, respectively, of 1,5-dideoxy- 1, 5-imino-D-glucitol (DNJ) by methods analogous to the N- butylation of DNJ as described in Example 2 of U.S. Patent No. 4,639,436 by substituting an equivalent amount of n-nonylaldehyde or n-decylaldehyde for n-butylraldehyde.
• the starting materials are readily available from many commercial sources. For example, DNJ is available from Sigma, St. Louis, MO.
• n-Nonylaldehyde also known as 1-nonanal or pelargonaldehyde
• n-decylaldehyde also known as decanal
• Aldrich Milwaukee, WI . It will be appreciated, however, that the method of the invention is not limited to any particular method of ⁇ ynthesi ⁇ of the N-nonyl-DNJ, N-decyl-DNJ, or other long-chain N-alkyl derivative ⁇ of DNJ.
• the N-nonyl-DNJ, N-decyl-DNJ, and other long-chain N-alkyl derivatives of DNJ can be used for treatment of patients afflicted with Gaucher 's disease and other glycolipid storage diseases by conventional methods of administering therapeutic drugs.
• the active compound is preferably formulated with pharmaceutically acceptable diluents and carriers.
• the active drug can be used in the free amine form or the salt form.
• Pharmaceutically acceptable salt form ⁇ are illu ⁇ trated, e.g., by the HC1 salt.
• the amount of the active drug to be administered must be an effective amount, that is, an amount which is medically beneficial against Gaucher ' ⁇ di ⁇ ease or other glycolipid storage disea ⁇ e but does not present adver ⁇ e toxic effects which overweigh the advantages that accompany its use. It would be expected that the adult human daily do ⁇ age would normally range from about 0.1 to about 1000 milligram ⁇ of the active compound.
• Suitable formulations of the active compound in pharmaceutically acceptable diluents and carriers in therapeutic dosage form can be prepared by the person skilled in the art by reference to general texts and treati ⁇ e ⁇ in the pharmaceutical field ⁇ uch as, for example, Remington ' ⁇ Pharmaceutical Sciences r Ed. Arthur Osol, 16 ed., 1980, Mack Publishing Co., Easton, PA, and 18th ed. , 1990.
• glycolipid ⁇ torage di ⁇ ea ⁇ es to which the method of the invention is directed are, e.g., Tay-Sachs disease, Sandhoff disease, Fabry disease, GM1 ganglio ⁇ idosi ⁇ and fucosidosis.
• FIG. 1 shows ⁇ thin layer chro atography of (a) CHO and (b) HL-60 treated cells. Cells were cultured for four day ⁇ in the pre ⁇ ence of radiolabelled palmitic acid and the following concentrations of compound:
• FIG. 2 in two parts, FIG.2a and FIG.2b, shows double reciprocal plots of the inhibition of the ceramide glucosyltransferase by N-butyl-DNJ (NB-DNJ) .
• NB-DNJ N-butyl-DNJ
• FIG. 3 shows inhibition of HL-60 cell ceramide gluco ⁇ yltran ⁇ fera ⁇ e activity by N-butyl-DNJ (open circles) and N-nonyl-DNJ (closed circles) .
• Activity was expres ⁇ ed as a percentage of control without inhibitor and the IC 50 values calculated from the rate curves shown.
• FIG. 4 shows structural relationship between NB-DNJ and ceramide glucosyltransferase ⁇ ub ⁇ trate.
• Radiolabelled N-butyl-DNJ (FIG.5B) and N-nonyl-DNJ (FIG.5A) were added to cultured CHO, MDBK and HepG2 cells for the times indicated. Cells were extensively washed and acid precipitated. After solution in NaOH, cell associated radioactivity was determined as a percentage of radiolabelled compound added.
• FIG. 6 is a bar graph which shows organ distribution of radiolabelled N-butyl-DNJ (NB-DNJ) and N-nonyl-DNJ (NN-DNJ) .
• Mouse body fluids and organs were collected for different times after gavage with radiolabelled compound. Radioactivity in each sample was determined and expressed as a percentage of radioactivity recovered.
• FIG. 7 shows the structures of N-alkylated deoxynojirimycin exemplified herein. Note that the C16 and C18 N-alkyl chains contain an unsaturated bond at ten and twelve carbon atoms from the nitrogen, respectively, whereas the others are saturated.
• FIG. 8 shows Inhibitory Constants of C4 to C18 DNJ Analogs for Ceramide Glucosyltransferase and ⁇ -Gluco ⁇ ida ⁇ e.
• FIG.8 contain ⁇ additional data to those seen in FIG.3 showing inhibition constants (IC 50 , ⁇ M) for the N-alkyl series measured against ceramide glucosyltransfera ⁇ e (CerGlcT) and ⁇ -gluco ⁇ ida ⁇ e. The trend is similar to the FIG.3 description - increasing chain length increases inhibition for glucosyltransferase, but not for glucosidase.
• FIG. 9 shows C4 to C18 DNJ Analog Uptake in MBDK Cells in which radioactivity incorporation/cpm protein i ⁇ plotted again ⁇ t time in hours (h) .
• FIG.9 ⁇ how ⁇ additional data to tho ⁇ e ⁇ hown in FIG.5 using C4-C18 N-alkylated DNJ compounds. Trend is apparent - increasing chain length increases cellular uptake in a time-dependent fashion. The double bond has some effect here ⁇ ince the unsaturated C16 and C18 analogs show ⁇ imilar kinetics to the fully saturated CIO and C12 analogs, respectively.
• FIG. 10 shows Distribution of N-Alkylated DNJ Analogs in Mouse Liver.
• FIG.10 shows the results of oral gavage with radiolabelled N- alkylated compounds using methods described in FIG.6.
• Short chain compounds (C4-C6) are rapidly cleared in a time-dependent manner.
• the C9 and CIO compounds show increased deposition and ⁇ lower clearance.
• the C12 to C18 analogs show the reverse trend, i.e., reduced appearance in the liver but this increases with time.
• FIG. 11 shows Distribution of N-alkylated DNJ Analogs in Mouse Brain. The radioactivity recovered (%) is plotted against N-alkyl chain length (C4 to C18) for 30 minute ⁇ (clear bar ⁇ ) , 60 minutes (shaded bar ⁇ ) and 90 minute ⁇ (filled, black bar ⁇ ).
• FIG.11 shows that the progressive accumulation that is also seen in the brain has slowed kinetics suggesting that there is reduced adsorption of longer alkyl chain compounds from the gut.
• FIG. 12 is a series of four bar charts, A, B, C and D, in which radioactivity (cpm) found in the liver is plotted against time post gavage in hours (h) with four different N-alkyl analogs of deoxynojirimycin (DNJ) .
• the four analogs shown are:; FIG.12A, N-butyl(C4); FIG.12B, N-nonyl (C9) ; FIG.12C, N-dodecyl (C12) ; FIG.12D, N-cis-13-octadecenyl (C18).
• FIG.12 shows that in the liver the majority of radioactive C4 is found after 1.5 h but with increasing chain length the clearance time is gradually increased with C18 showing significant deposition at 24 h post gavage.
• FIG. 13 is a series of four bar charts, A, B, C and D, in which radioactivity (cpm) found in the brain is plotted against time post gavage in hours (h) with the same analog compounds as in FIG.12.
• the four analogs shown are: FIG.13A, N-butyl (C4) ; FIG.13B, N-nonyl (C9) ; FIG.13C, N-dodecyl (C12); FIG.13D, N-cis- 13-octadecenyl (C18) .
• FIG.13 shows that the same effect a ⁇ in the liver in FIG.12 i ⁇ ⁇ een in the brain but at much longer time points, reflecting reduced transmission from the gut to blood and hence, brain.
• FIG. 14 shows ⁇ Imino Sugar (N-alkyl DNJ) Binding to Serum Protein.
• FIG.14 shows the protein binding capacity of N-alkylated compounds. Short chain compounds (C4-C6) bind poorly but those larger than CIO are almost completely bound to protein. The C8 and C9 analogs appear to favor equally, protein and solution phase.
• the radiolabelled lipids were separated by TLC (FIG.l) and bands corresponding to gluco ⁇ ylceramide and lactosyl- cera ide were quantitated by scanning densitometry to estimate the reduction in glycolipid biosynthe ⁇ i ⁇ .
• the ⁇ e data were plotted to obtain inhibitory con ⁇ tants (IC 50 ) for both cell lines and compounds (Table 1) .
• N-nonyl-DNJ has a 10-fold increa ⁇ ed potency over N-butyl-DNJ in inhibiting ceramide glucosyltransfera ⁇ e in in vitro assay ⁇ (IC 50 values of 2.8 ⁇ M and 27.1 ⁇ M respectively, see FIG.3).
• alkylated deoxynojirimycin compounds The mechanism of action of alkylated deoxynojirimycin compounds is proposed to be that of ceramide mimicry and a model demonstrating thi ⁇ mimicry at the molecular level is shown in FIG.4.
• An energy minimized molecular model of NB-DNJ and ceramide predicts structural ho ology of three chiral centers and the N-alkyl chain of NB-DNJ, with the trans- alkenyl and N-acyl chain of ceramide.
• Thi ⁇ increased in vitro potency does not explain the dramatic difference in inhibition of glycolipid biosynthe ⁇ i ⁇ in cellular ⁇ ystems.
• N-nonyl-DNJ was increased by 3.5-5 fold. It is clearly the combination of the inhibitory effect and increased uptake that is important in potentiating the inhibition by N-nonyl-DNJ.
• N-decyl-DNJ shows inhibition at 50 times lower concentrations than N-butyl-DNJ in the HL-60 cell-based as ⁇ ay de ⁇ cribed above.
• the long-chain N-alkyl derivatives of DNJ are effective for treatment of glycolipid storage di ⁇ ea ⁇ es.
• Example I The laboratory procedures of Example I were carried out to further demonstrate the advantage of the long-chain N-alkyl derivatives of deoxynojirimycin compared to the short-chain analogs for the treatment of glycolipid storage di ⁇ eases.
• the chemical structures of the analogs compared in this Example are shown in Figure 7. These analogs are saturated except the C16 and C18 alkyl chain analogs which are mono-un ⁇ aturated.
• the inhibition con ⁇ tants (IC 50 ) for the N-alkyl series measured against ceramide glycosyltransferase (CerGlcT) and alpha-glucosida ⁇ e are ⁇ hown in Figure 8.
• the trend is similar to that ⁇ hown in Figure 3 in which increasing chain length increases inhibition for glycosyltransferase, but not for glucosidase.
• the optimal chains length appears to be CIO (decyl) .
• Figure 9 confirms the trend ⁇ hown in Figure 5 in which increasing chain length increases cellular uptake in a time dependent manner.
• the effect of the double bond in the C16 and C18 analogs is seen in that the C16 shows similar kinetics to the saturated CIO analog, and the C18 shows similar kinetics to the saturated C12 analog.
• Figure 11 shows the progre ⁇ ive accumulation that i ⁇ also seen in the mouse brain has slowed kinetics and thereby ⁇ uggests that there is a reduced adsorption of the longer chain alkyl analogs from the gut.
• Figures 12 and 13 Further evidence of reduced adsorption is shown in Figures 12 and 13 when longer time points post gavage are u ⁇ ed to monitor ti ⁇ ue depo ⁇ ition. Thu ⁇ , Figure 12 shows that in the liver the majority of radioactive C4 is found after 1.5 hours, but with increasing chain length the clearance time is gradually increased, with C18 showing significant deposition at 24 hours post gavage. Figure 13 shows that the same effect is ⁇ een in the mou ⁇ e brain but at much longer time point ⁇ , reflecting reduced tran ⁇ mi ⁇ sion from the gut to the blood and hence the brain.
• Figure 14 shows the protein binding capacity of the N- alkylated analogs of deoxynojirimycin.
• the short-chain analogs (C4 to C6) bind poorly but those larger than CIO are almost completely bound to protein.
• the C8 and C9 analog ⁇ appear to favor equally, protein and ⁇ olution phase.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22339901

Family Applications (1)

Country Status (11)

Cited By (12)

Families Citing this family (24)

Citations (2)

Family Cites Families (5)

• 1999
  • 1999-12-02 US US09/453,754 patent/US6610703B1/en not_active Expired - Fee Related
  • 1999-12-08 AT AT99967135T patent/ATE226821T1/de not_active IP Right Cessation
  • 1999-12-08 CA CA002352544A patent/CA2352544C/en not_active Expired - Fee Related
  • 1999-12-08 DE DE69903750T patent/DE69903750T2/de not_active Expired - Fee Related
  • 1999-12-08 ES ES99967135T patent/ES2190674T3/es not_active Expired - Lifetime
  • 1999-12-08 WO PCT/US1999/027918 patent/WO2000033843A1/en not_active Ceased
  • 1999-12-08 EP EP99967135A patent/EP1137416B1/en not_active Expired - Lifetime
  • 1999-12-08 JP JP2000586335A patent/JP2002531505A/ja active Pending
  • 1999-12-08 PT PT99967135T patent/PT1137416E/pt unknown
  • 1999-12-08 AU AU23475/00A patent/AU2347500A/en not_active Abandoned
  • 1999-12-08 DK DK99967135T patent/DK1137416T3/da active

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events